Clinical trials: Insulin-dependent Diabetes Mellitus
Diabetes Mellitus, Insulin-Dependent
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
The objective of this clinical trial is to investigate whether ladarixin has sufficient activity (preservation of β-cell function and slow-down of the progression of T1D) to warrant its further development (proof of concept…
- Trial name
- NCT02814838
- Testing
- Ladarixin
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes, Nephropathy
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).
- Trial name
- NCT00308347
- Testing
- MK0954, losartan / Duration of Treatment: mean 3.4 years
- Volunteers
- 1,513 people
- Sponsor
- Organon and Co
Solid Tumor, Lymphoma
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in…
- Trial name
- NCT03013491
- Testing
- CX-072, ipilimumab, vemurafenib
- Where
- 31 sites in United States, Netherlands and 4 more
- Volunteers
- 196 people
- Sponsor
- CytomX Therapeutics
Type 1 Diabetes
Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID Use
Obtain preliminary safety and performance data on a settings initialization and adaptation algorithm used in conjunction with closed-loop control.
- Trial name
- NCT05204134
- Testing
- Automated Insulin Delivery Settings Initialization and Adaptation Algorithm
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Insulin-Dependent
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
The study is a prospective, multi-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the blood when the insulin is…
- Trial name
- NCT01216618
- Testing
- InsuPatch
- Where
- 3 sites in United States, Israel
- Volunteers
- 55 people
- Sponsor
- Insuline Medical Ltd.
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
Type 1 Diabetes Mellitus
Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)
The purpose of this pilot study is to evaluate performance of the SEVEN System and the Navigator System when both devices are worn concurrently by subjects with type 1 diabetes mellitus.
- Trial name
- NCT00939289
- Testing
- Continuous Glucose Monitoring
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- DexCom, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to test for bioequivalence between two formulations of insulin degludec/insulin aspart (IDegAsp) to see if the efficacy and safety obtained with formulation 1 can be…
- Trial name
- NCT01455142
- Testing
- insulin degludec/insulin aspart
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
A Continuous Glucose Monitor Based Insulin Bolus Calculator
This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor
- Trial name
- CGM-IBC (NCT05229445)
- Testing
- continuous glucose monitor based insulin bolus calculator
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Welldoc
Diabetes Mellitus Type 1
A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes
This crossover, glucose-clamp study will investigate the impact of different basal insulin infusion rates on glucose control employing insulin pumps with different insulin delivery regimen.
- Trial name
- NCT00772356
- Testing
- Accu-Chek Spirit Insulin Pump, Comparator insulin pump
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 1
To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1
This study is conducted in Africa. The aim of this study is to estimate the percentage of children and adolescents below or equal to 15 years in Tunisia with acceptably controlled diabetes mellitus type 1.
- Trial name
- NCT01493388
- Testing
- insulin
- Where
- Tunisia
- Volunteers
- 402 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes
The purpose of this early feasibility study is to assess the predictive low glucose suspend (PLGS) feature's safety, functionality and performance.
- Trial name
- NCT03890003
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Healthy, Type 1 Diabetes Mellitus
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT06280703
- Testing
- LY3938577, Insulin Degludec, Insulin Lispro
- Where
- Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes
The primary study objective was to compare the rate of "all hypoglycemia" (composite outcome of the following hypoglycemia events: symptomatic hypoglycemia episodes, low continuous glucose monitoring system (CGMS) excursions…
- Trial name
- PRESCHOOL (NCT00993473)
- Testing
- Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
- Where
- 61 sites in United States, Austria and 14 more
- Volunteers
- 125 people
- Sponsor
- Sanofi
Clamp Study
A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients
Pharmacokinetics and pharmacodynamics study of 2 formulation of insulin glargine (RinGlar® GEROPHARM vers. Lantus® Sanofi-Aventis)
- Trial name
- NCT04101383
- Testing
- RinGlar®, Lantus®
- Where
- 2 sites in Russia
- Volunteers
- 42 people
- Sponsor
- Geropharm
Type 1 Diabetes
Omnipod 5 System Compared to Pump Therapy
Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or…
- Trial name
- NCT05409131
- Testing
- Omnipod 5 System
- Where
- 14 sites in United States, France
- Volunteers
- 196 people
- Sponsor
- Insulet Corporation
Diabetes, Diabetes Mellitus, Type 1
A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
This is an inpatient treatment, double-blind, randomized, 3-way crossover study in T1DM subjects using insulin pump therapy.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
- Trial name
- NCT04956263
- Testing
- YG1699, Dapagliflozin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Youngene Therapeutics Inc., Ltd.
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port
This study investigated wearability and usability of the I-PORT™ Injection Port (I-PORT™), a new disposable injection port through which prescribed medication is injected subcutaneously from a standard syringe or pen.
- Trial name
- NCT00486109
- Testing
- I-Port(TM) Injection Port
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Patton Medical Devices
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.